Despite being the most promising target in the pathology of Alzheimer’s disease, the AChE drugs approved by the FDA, namely, rivastigmine, donepezil, and galantamine, only provide symptomatic treatment. The gene discussed is ACHE; the disease is Alzheimer disease.